氟比洛芬治疗类风湿关节炎、骨关节炎及强直性脊柱炎

目的 :观察氟比洛芬治疗类风湿关节炎、骨关节炎及强直性脊柱炎的疗效和不良反应。方法 :80例类风湿关节炎病人随机分为氟比洛芬组 50例 ,双氯芬酸组 30例。 4 0例骨关节炎病人分为氟比洛芬组 2 0例 ,双氯芬酸组 2 0例。氟比洛芬组口服氟比洛芬 50mg ,po ,tid× 4wk ;双氯芬酸组口服双氯芬酸 2 5mg ,po ,tid× 4wk。 38例强直性脊柱炎均为氟比洛芬组 ,口服氟比洛芬 10 0mg ,po ,tid×4wk。结果 :在氟比洛芬组中类风湿关节炎组和骨关节炎组的疗效分别为 86%和 85% ,双氯芬酸组为87%和 80 % ,2组差异无显著意义 (P >0 .0 5)。强直性脊柱炎组的疗效为 79%。不良反应发生率氟比洛芬组和双氯芬酸组分别为 19%和 30 % ,氟比洛芬组明显低于双氯芬酸组 (P <0 .0 5)。结论 :氟比洛芬是一种安全有效的新型非甾体消炎止痛药

Flurbiprofen in treating rheumatoid arthritis, osteoarthritis and ankylosing spo ndylitis

AIM: To observe the efficacy of the flurbiprofen in treating rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. METHODS: Eighty patients with rheumatoid arthritis were radomly divided into 2 groups. Fifty patients (M 9,F 41;age 47 a± s 12 a) of flurbiprofen group were treated with flurbiprofen 50 mg, po ,tid for 4 wk; 30 patients (M 5, F 25; age 46 a±10 a) of diclofenac group were treated with diclofenac 25 mg, po , tid for 4 wk. Forty patients with osteoarthritis were also divided into 2 groups. Twenty patients (M 6, F 14; age 56 a±12 a) of flurbiprofen group were treated with flurbiprofen 50 mg, po , tid for 4 wk; the other patients (M 7, F 13; age 56 a± s 12 a) of diclofenac group were treated with diclofenac 25 mg, po, tid for 4 wk. Thirty eight patients with ankylosing spondylitis (M 33, F 5; age 33 a±11 a) were treated with flurbiprofen 100 mg, po , tid for 4 wk. RESULTS: The effective rates of flurbiprofen and diclofenac for rheumatoid arthritis and osteoarthritis group were 86%, 87% and 85%, 80% ( P >0.05). For ankylosing spondylitis group the effective rate of flurbiprofen was 79%. The rates of adverse reaction of flurbiprofen and diclofenac groups were respectively 19% and 30%. The rates of adverse reaction of flurbiprofen was lower than dicolofenac ( P < 0.05 ). CONCLUSION: Flurbiprofen is efficacious and safe in treating rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.